India's $130-billion pharma ambition faces compliance bottlenecks, manufacturing delays: Report

India's pharmaceutical industry, which aims to reach a value of $130 billion, is facing significant challenges in meeting its ambitious growth targets. Compliance bottlenecks and manufacturing delays are major hurdles that the sector needs to overcome, according to a recent report. The report highlights a backlog of open manufacturing incidents at USFDA-approved formulation plants in India, which could impact the country's ability to meet its pharmaceutical export targets and maintain its reputation as a reliable supplier of high-quality medicines.

Why it matters

India's pharma sector faces compliance bottlenecks and manufacturing delays, which could hinder its growth ambitions. This may impact investor confidence and the sector's overall performance.

Market impact

Markets & countries in focus

Transmission channels

Likely winners & losers

Explore the intelligence

MeridStreet does not reproduce source articles. The summary and analysis above are generated by MeridStreet from public headlines and its own market model; the original reporting belongs to Moneycontrol. For information only — not financial advice.